Crinetics Pharmaceuticals, Inc. CRNX
Key Stats
- Today's Range
- $83.47 – $83.80
- 50-Day Range
- $32.30 – $84.00
- 52-Week Range
- $25.83 – $84.00
- Volume
- 1.86 million shs
- Average Volume
- 6.45 million shs
- Market Cap
- $8.85 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 6.91
- Price / Sales
- 489.87
Short Interest
- Short Interest
- 0.10%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $18.07 million
- Net Income
- $-496,388,000
- Net Margin
- -2747.18%
- Return on Equity
- -38.76%
- Debt-to-Equity
- —
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.